Gene Liau, EVP Research & Preclinical Development at Stoke Therapeutics, Inc. (STOK), sold 7,639 shares at $63.52 ($480K) on 2021-03-02, disclosed to the SEC on 2021-03-04.
Open-market sale of $480k STOK by EVP Research & Preclinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $58.73 | 149 | $9K | 1.8% |
| 2 | $62.46 | 2,295 | $143K | 29.9% |
| 3 | $62.46 | 2,295 | $143K | 29.9% |
| 4 | $63.52 | 2,900 | $184K | 38.4% |
| Total | $62.79 avg | 7,639 | $480K | 100% |
| Filing → |
| STOK | SELL | 2020-06-03 | $1.0M | — | Filing → |
| STOK | SELL | 2020-05-26 | $225K | — | Filing → |